Outbreak of Marburg virus
The Marburg virus
was responsible for an outbreak of haemorrhagic illness in Germany and the former Yugoslavia in the 1960s, following importation of monkeys from Africa for research purposes.
Clinical reports of past Marburg virus
outbreaks suggest that people can be exposed longer to the virus than monkeys before showing symptoms.
For Ebola virus proteins from the Zaire and Sudan strains and the Marburg virus
protein, scientists from the NIAID formulated the DNA vaccines that code and vaccines comprises the construction plans for the proteins on the outer surface of the virus.
Seasonal pulses of Marburg virus
circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection.
Investigators conducted two pilot studies in cynomolgus monkeys to assess the efficacy of AVI-6003 against lethal challenge with Marburg virus
In monkeys, an experimental vaccine prevented infection by the lethal Marburg virus
From the beginning, it was realized CDC must have the capacity to deal with this virus and that Marburg virus
was dangerous, calling for the best biocontainment of the day.
A single injection of an experimental vaccine prevents infection by the lethal Marburg virus
in monkeys, a study finds.
In addition, preclinical studies conducted with investigators from the Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB) at Galveston and the National Institutes of Health (NIH) have shown that a single dose of the VesiculoVax(TM) Ebola vaccine is able to protect non-human primates against lethal challenge with the highly pathogenic, low-passage isolates of the Zaire and Sudan species of Ebola virus, and that a single dose of the VesiculoVax(TM) Marburg vaccine is able to protect non-human primates against lethal challenge with a highly pathogenic, low-passage isolate of the Angola species of Marburg virus
Filoviruses, which comprise 4 Ebola viruses pathogenic to humans and 1 Marburg virus
species, have caused multiple outbreaks of hemorrhagic fever primarily in central and eastern Africa (13,14).
To make the vaccines, the researchers stripped the vesicular stomatitis virus of a particular gene and replaced it either with a gene that encodes a protein on the Marburg virus
or with a gene for a protein on the Ebola virus.
Some examples include: Lassa fever, Marburg virus
, Ebola virus, Bolivian haemorrhagic fever, Korean hemorrhagic fever, Crimean-Congo hemorrhagic fever and Dengue hemorrhagic fever.
In addition, a single dose of the Profectus VesiculoVax(TM)rVSV-vectored Marburg vaccine provided 100% protection against challenge with 1,000 times the lethal dose of low passage Marburg virus
For the first time, researchers at the University of Texas Medical Branch at Galveston, in partnership with Tekmira Pharmaceuticals, have protected nonhuman primates against Marburg virus
Angola hemorrhagic fever.